Background: Inflammation during primary percutaneous coronary intervention (PCI) has negative outcomes. Colchicine's anti-inflammatory effects may reduce cardiovascular risks in acute myocardial infarction, but evidence post-PCI is limited.
Aim: The efficacy of colchicine therapy in reducing inflammation and adverse ischemic cardiovascular events in patients with ST segment elevation myocardial infarction (STEMI) managed by primary PCI.
Methods: A randomized, controlled patients with STEMI were randomly assigned to the intervention colchicine group in addition to standard therapy versus the other group who received the standard therapy alone. The primary end point was a composite of all death, spontaneous myocardial infarction (MI), resuscitated cardiac arrest, ischemic stroke, ischemia-driven coronary revascularization or hospitalization for unstable angina at 6 months follow up. The secondary end points were components of the primary end point and the group difference in cardiac systolic function by echocardiography from baseline to 1 month after PCI.
Results: A total of 267 patients underwent randomization during February 2022 to February 2024; 89 patients were randomized into the colchicine group, 93 patients in the control groups and 85 patients were excluded. The primary-outcome event was similar between both groups (21 events in colchicine group Vs 26 events in control group, Log Rank test 0.451). The incidence of individual components of the primary outcome appeared to be similar in the two groups. There was no difference in systolic function by echocardiography between the two groups.
Conclusions: The addition of colchicine did not yield a significant benefit in enhancing the outcomes of patients with STEMI at a 6-month follow-up.
Keywords: Colchicine, Primary PCI, STEMI, Cardiovascular events
How to cite this article: Ibrahim M, ElHawry A, Oraby M, Abdel Shafee M, Sabbah M., Effect of Colchicine Treatment in Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction. Int J Drug Deliv Technol. 2026;16(3s): 354-359; DOI: 10.25258/ijddt.16.3s.45